---
title: "Natera, Inc. (NTRA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NTRA.US.md"
symbol: "NTRA.US"
name: "Natera, Inc."
industry: "Biotechnology"
datetime: "2026-06-13T22:01:40.527Z"
locales:
  - [en](https://longbridge.com/en/quote/NTRA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NTRA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NTRA.US.md)
---

# Natera, Inc. (NTRA.US)

## Company Overview

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.natera.com](https://www.natera.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-13T04:30:12.000Z

**Overall: B (0.36)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 10 / 390 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 36.59% |  |
| Net Profit YoY | -19.26% |  |
| P/B Ratio | 17.12 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 30371686060.74 |  |
| Revenue | 2500927000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -15.02% | E |
| Profit Margin | -9.05% | D |
| Gross Margin | 64.71% | A |
| Revenue YoY | 36.59% | A |
| Net Profit YoY | -19.26% | D |
| Total Assets YoY | 50.91% | A |
| Net Assets YoY | 43.10% | A |
| Cash Flow Margin | -93.24% | E |
| OCF YoY | 36.59% | A |
| Turnover | 1.15 | A |
| Gearing Ratio | 32.14% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Natera, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "36.59%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-19.26%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "17.12",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "30371686060.74",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2500927000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "-15.02%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-9.05%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "64.71%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "36.59%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-19.26%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "50.91%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "43.10%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-93.24%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "36.59%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "1.15",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "32.14%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -134.20 | 545/390 | - | - | - |
| PB | 17.12 | 417/390 | 24.86 | 18.44 | 16.57 |
| PS (TTM) | 12.14 | 178/390 | 14.71 | 12.54 | 11.64 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | CapForce Inc. (CFOR.US) | A | A | A | A | B | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-12T04:00:00.000Z

Total Analysts: **21**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 13 | 62% |
| Overweight | 5 | 24% |
| Hold | 3 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 212.07 |
| Highest Target | 300.00 |
| Lowest Target | 193.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/NTRA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/NTRA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/NTRA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/NTRA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**